18 research outputs found
Radiolabeled dendrimer coated nanoparticles for radionuclide imaging and therapy: a systematic review
Background: Dendrimers are nanoscale-size polymers with a globular structure. They
are composed of an internal core and branching dendrons with surface active groups which can
be functionalized for medical applications. Different complexes have been developed for imaging
and therapeutic purposes. This systematic review aims to summarize the development of newer
dendrimers for oncological applications in nuclear medicine. Methods: An online literature search
was conducted on Pubmed, Scopus, Medline, Cochrane Library, and Web Of Science databases
selecting published studies from January 1999 to December 2022. The accepted studies considered
the synthesis of dendrimer complexes for oncological nuclear medicine imaging and therapy. Results:
111 articles were identified; 69 articles were excluded because they did not satisfy the selection criteria.
Thus, nine duplicate records were removed. The remaining 33 articles were included and selected for
quality assessment. Conclusion: Nanomedicine has led researchers to create novel nanocarriers with
high affinity for the target. Dendrimers represent feasible imaging probes and therapeutic agents
since, through the functionalization of external chemical groups and thanks to the possibility to carry
pharmaceuticals, it can be possible to exploit different therapeutic strategies and develop a useful
weapon for oncological treatments
PET imaging of neuro-inflammation with tracers targeting the translocator protein (TSPO), a systematic review: from bench to bedside
Parkinson’s disease is the second most common neurodegenerative disorder, affecting
2–3% of the population of patients >65 years. Although the standard diagnosis of PD is clinical,
neuroimaging plays a key role in the evaluation of patients who present symptoms related to
neurodegenerative disorders. MRI, DAT-SPECT, and PET with [18F]-FDG are routinely used in the
diagnosis and focus on the investigation of morphological changes, nigrostriatal degeneration or
shifts in glucose metabolism in patients with parkinsonian syndromes. The aim of this study is to
review the current PET radiotracers targeting TSPO, a transmembrane protein that is overexpressed
by microglia in another pathophysiological process associated with neurodegenerative disorders
known as neuroinflammation. To the best of our knowledge, neuroinflammation is present not only
in PD but in many other neurodegenerative disorders, including AD, DLB, and MSA, as well as
atypical parkinsonian syndromes. Therefore, in this study, specific patterns of microglial activation in
PD and the differences in distribution volumes of these radiotracers in patients with PD as compared
to other neurodegenerative disorders are reviewed
Fibroblast activation protein inhibitor (FAPI)-based theranostics-where we are at and where we are heading: a systematic review
Cancer is the leading cause of death around the globe, followed by heart disease and stroke, with the highest mortality to this day. We have reached great levels of understanding of how these various types of cancer operate at a cellular level and this has brought us to what we call "precision medicine" where every diagnostic examination and the therapeutic procedure is tailored to the patient. FAPI is among the new tracers that can be used to assess and treat many types of cancer. The aim of this review was to gather all the known literature on FAPI theranostics. A MEDLINE search was conducted on four web libraries, PUBMED, Cochrane, Scopus, and Web of Sciences. All of the available articles that included both diagnoses and therapy with FAPI tracers were collected and put through the CASP (Critical Appraisal Skills Programme) questionnaire for systematic reviewing. A total of 8 records were deemed suitable for CASP review, ranging from 2018 to November 2022. These studies were put through the CASP diagnostic checklist, in order to assess the goal of the study, diagnostic and reference tests, results, descriptions of the patient sample, and future applications. Sample sizes were heterogeneous, both for size as well as for tumor type. Only one author studied a single type of cancer with FAPI tracers. Progression of disease was the most common outcome, and no relevant collateral effects were noted. Although FAPI theranostics is still in its infancy and lacks solid grounds to be brought into clinical practice, it does not show any collateral effects that prohibit administration to patients, thus far, and has good tolerability profiles
PET criteria by cancer type from imaging interpretation to treatment response assessment: beyond FDG PET score
Background: in recent years, the role of positron emission tomography (PET) and
PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide variety of
pathological conditions. This review aims to collect and review PET criteria developed for interpretation
and treatment response assessment in cases of non-[18F]fluorodeoxyglucose ([18F]FDG) imaging
in oncology. Methods: A wide literature search of the PubMed/MEDLINE, Scopus and Google
Scholar databases was made to find relevant published articles about non-[18F]FDG PET response
criteria. Results: The comprehensive computer literature search revealed 183 articles. On reviewing
the titles and abstracts, 149 articles were excluded because the reported data were not within the
field of interest. Finally, 34 articles were selected and retrieved in full-text versions. Conclusions:
available criteria are a promising tool for the interpretation of non-FDG PET scans, but also to assess
the response to therapy and therefore to predict the prognosis. However, oriented clinical trials are
needed to clearly evaluate their impact on patient management
Novel Theranostic Approaches Targeting CCR4-Receptor, Current Status and Translational Prospectives: A Systematic Review
Background: With the high mortality rate of malignant tumors, there is a need to find novel theranostic approaches to provide an early diagnosis and targeted therapy. The chemokine receptor 4 (CCR4) is highly expressed in various tumors and plays an important role in tumor pathogenesis. This systematic review aims to provide a complete overview on clinical and preclinical applications of the CCR4 receptor as a target for theranostics, using a systematic approach to classify and assemble published studies performed on humans and animals, sorted by field of application and specific tumor. Methods: A systematic literature search of articles suiting the inclusion criteria was conducted on Pubmed, Scopus, Central, and Web of Science databases, including papers published from January 2006 to November 2022. Eligible studies had to be performed on humans and/or in vivo/in vitro studying CCR4 expression in tumors. The methodological quality was assessed through the Critical Appraisal Skills Programme (CASP) assessing only the studies performed on humans. Results: A total of 17 articles were screened. The articles were assessed for eligibility with the exclusion of 4 articles. Ultimately, 13 articles were selected for the qualitative analysis, and six articles were selected for the critical appraisal skills program. Conclusions: The development of new radionuclides and radiopharmaceuticals targeting CCR4 show promising results in the theranostics of CCR4 sensible tumors. Although to widen its use in clinical practice, further translation of preclinical to clinical data is needed
Gastrin-releasing peptide receptor agonists and antagonists for molecular imaging of breast and prostate cancer: from pre-clinical studies to translational perspectives
Introduction Prostate and breast cancer represent a leading cause of cancer-related death worldwide with a dramatic social and demographic impact. Gastrin-releasing peptide receptors (GRPRs), part of the bombesin (BBN) family, have been found overexpressed in both the aforementioned malignancies, and have emerged as a potentially useful target to combine imaging and therapy in a unique, synergistic approach, namely 'theranostics.' Areas Covered The biological characteristics of GRPRs, as well as their aberrant expression in breast and prostate cancer, are covered. Furthermore, the role of the different available GRPR agonists and antagonists, labeled with radionuclides suitable for molecular imaging through single photon computed tomography (SPECT) or positron emission computed (PET/CT), is reviewed, with a particular focus on the potential theranostic implications. Expert opinion GRPR-targeted molecular imaging of breast and prostate cancer gave promising results in pre-clinical studies. Notably, GRPRs' expression was found to be inversely correlated with disease progression in both prostate and breast cancer. Among the different GRPR agonists and antagonists applied as imaging probes, RM26 presented particularly interesting applications, with meaningful theranostic potential, but its diagnostic performance resulted highly influenced by the choice of the chelator-radionuclide complex, being long-life radionuclides more suitable for obtaining high-contrast imaging
Radiotheranostic agents targeting neuroblastoma: state-of-the-art and emerging perspectives
Neuroblastoma (NB) represents the most common extracranial tumor of childhood. Prognosis
is quite variable, ranging from spontaneous regression to aggressive behavior with wide
metastatization, high mortality, and limited therapeutic options. Radiotheranostics combines a
radiopharmaceutical pair in a unique approach, suitable both for diagnosis and therapy. For many
years, metaiodobenzylguanidine (MIBG), labeled with 123I for imaging or 131I for therapy, has represented
the main theranostic agent in NB, since up to 90% of NB incorporates the aforementioned
radiopharmaceutical. In recent years, novel theranostic agents hold promise in moving the field
of NB radiotheranostics forward. In particular, SarTATE, consisting of octreotate targeting somatostatin
receptors, has been applied with encouraging results, with 64Cu-SARTATE being used for
disease detection and with 67Cu-SARTATE being used for therapy. Furthermore, recent evidence
has highlighted the potential of targeted alpha therapy (TAT) for treating cancer by virtue of alpha
particles’ high ionizing density and high probability of killing cells along their track. On this path,
211At-astatobenzylguanidine (MABG) has been developed as a potential agent for TAT and is actually
under evaluation in preclinical NB models. In this review, we performed a web-based and desktop
literature research concerning radiotheranostic approaches in NB, covering both the radiopharmaceuticals
already implemented in clinical practice (i.e.,123/1311-MIBG) and those still in a preliminary
or preclinical phase
Medication and ECG Patterns That May Hinder SPECT Myocardial Perfusion Scans
Coronary artery disease (CAD) is the leading cause of death followed by cancer, in men and women. With risk factors being endemic and the increasing costs of healthcare for management and treatment, myocardial perfusion imaging (MPI) finds a central role in risk stratification and prognosis for CAD patients, but it comes with its limitations in that the referring clinician and managing team must be aware of and use at their advantage. This narrative review examines the utility of myocardial perfusion scans in the diagnosis and management of patients with ECG alterations such as atrioventricular block (AVB), and medications including calcium channel blockers (CCB), beta blockers (BB), and nitroglycerin which may impact the interpretation of the exam. The review analyzes the current evidence and provides insights into the limitations, delving into the reasons behind some of the contraindications to MPI
Role of Exendin-4 Functional Imaging in Diagnosis of Insulinoma: A Systematic Review
Background: Insulinomas are the most common neuroendocrine neoplasms of the pancreas. Diagnosis is made through patient clinical presentation with hypoglycemia symptoms and imaging, such as EUS, CT, MRI, and functional imaging. Exendin-4 PET/CT (and SPECT/CT) is a new prominent radiotracer developed to image insulinomas. The aim of the study is to evaluate whether exendin-4 imaging is a useful tool in imaging for insulinoma patients when other imaging methods do not reach them. Methods: MEDLINE research conducted on PubMed, Scopus, and Web of Science gathered a total of 501 papers. Studies that evaluated exendin-4 SPECT and PET in insulinoma patients were screened and assessed through QUADAS-2 for risk of bias and applicability concerns’ assessment. Sensitivity, specificity, and accuracy were reported when available. Results: A total of 13 studies were deemed eligible for a QUADAS 2 review. Studies included ranged from 2009 to 2022. The most-used tracer was 68Ga-DOTA-exendin-4 in PET and 111In-DTPA-exendin-4 in SPECT. Exendin-4 labeled with 99mTc was also reported. The QUADAS-2 risk of bias assessment was overall low, with some unclear reports in the reference and index domains. Only two domains were at high risk of bias because of an explicated non-blind imaging review. Applicability concerns for bias were low in all domains. Reported sensitivities ranged from 95% to 100% and specificities from 20% to 100%. Conclusions: exendin-4 imaging is a sensitive functional imaging tracer in both SPECT and PET applications, especially in suspicion of benign insulinomas located where endoscopic ultrasound cannot reach, being more sensitive than morfostructural imaging